Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ...
When most people think about cancer treatment, they picture chemotherapy, grueling surgeries, harsh drug regimens, and devastating side effects. Medicus ...
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2026 / New to The Street, the nationally syndicated, long-form ...
Investors were disappointed with Pro Medicus Limited's ( ASX:PME ) recent earnings release. Our analysis found ...
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets ...
The average one-year price target for Pro Medicus (OTCPK:PMCUF) has been revised to $165.74 / share. This is a decrease of 28.66% from the prior estimate of $232.32 dated February 3, 2026. The price ...
In April, Medicus Pharma Ltd. (NASDAQ:MDCX) agreed to acquire all of Antev’s issued and outstanding shares on a share exchange. Antev is a clinical-stage biotech company developing Teverelix, a ...
With its stock down 5.2% over the past three months, it is easy to disregard Pro Medicus (ASX:PME). But if you pay close attention, you might gather that its strong financials could mean that the ...
Medicus Pharma (MDCX) entered into non-binding letter of intent with Reliant AI to collaborate on the development of an artificial-intelligence-powered data analytics platform designed to support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results